The DXd ADC portfolio currently consists of ENHERTU, a HER2 directed ADC ... Rahway, NJ, USA. DS-3939, a TA-MUC1 directed ADC, is being developed by Daiichi Sankyo. The second Daiichi Sankyo ...

AstraZeneca already has a reputation when it comes to antibody-drug conjugates, having turned Enhertu into a blockbuster and then following it up with the FDA approval of another ADC, Datroway ...

US biotech Cartesian Therapeutics (Nasdaq: RNAC) has reported that patients with generalized myasthenia gravis (gMG) continued to experience lasting symptom relief 12 months after treatment with its ...

The lone unrated drug was trastuzumab deruxtecan (Enhertu). Thirty-nine of the rated drugs (80%) were classed as having a high added benefit, and 9 (18%) were classified as having a low added benefit.

The DXd ADC portfolio currently consists of ENHERTU, a HER2 directed ADC ... are being jointly developed and commercialized globally with Merck & Co., Inc, Rahway, NJ, USA. DS-3939, a TA-MUC1 directed ...

ENHERTU® Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 ...

The risk of disease progression or death was reduced by 79% with nivolumab/ipilimumab compared with chemotherapy. The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in ...

The EC previously approved AstraZeneca and Daiichi Sankyo’s Enhertu for use as a single agent in treating adults with unresectable or metastatic hormone receptor-positive, human epidermal growth ...

Opponents of President Donald Trump and billionaire Elon Musk rallied across the U.S. to protest the administration’s actions on government downsizing, the economy, human rights and other issues.